FLT3 and acute myeloid leukemia: Per the above in vitro and in vivo trials on the cohort of preclinical AML models thus far, FLT3-ITD seems to be one of the positive predictors for the response to narazaciclib in AML patients (Figs. 1B, 3, 4 and Supplemental Fig. S8 Right panel).